Wright Cameron D, Wain John C, Wong Daniel R, Donahue Dean M, Gaissert Henning A, Grillo Hermes C, Mathisen Douglas J
Division of General Thoracic Surgery, Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, Mass 02114, USA.
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1413-21. doi: 10.1016/j.jtcvs.2005.07.026. Epub 2005 Oct 13.
This study sought to define predictors of recurrence after resection of thymic tumors.
A single-institution retrospective study was performed of 179 patients who underwent resection of a thymic tumor from 1972 through 2003.
Resection was complete in 90% (161/179) of patients. After a median follow-up of 115 months, the recurrence rate was 11% (20/179), the tumor-related death rate was 7.8% (14/179), and the overall death rate was 36.3% (65/179). Tumor recurrence correlated with advanced stage and histology (P < .0001). The difference in recurrence between Masaoka stage I (0) and II (1.7% [1/59]) was insignificant. Recurrence rates correlated with World Health Organization tumor type: A and AB, 0%; B1 and B2, 8% (4/51); B3, 27% (14/51); and C, 50% (2/4; P < .0001). Tumor size separation into quintiles demonstrated a step-up of recurrence at 8 cm (<8 cm, 1.8% [2/113]; > or =8 cm, 28% [18/64]; P < .003). Multivariate Cox modeling demonstrated that Masaoka stage (odds ratio, 5.70; P < .001), World Health Organization histology (odds ratio, 5.77; P = .003), and size (odds ratio, 1.16; P = .001) were independent predictors of recurrence.
The Masaoka staging system could be collapsed to 3 degrees of invasion by combining stages I and II. The World Health Organization histologic type can be simplified for clinical use into A (A, AB), early B (B1, B2), advanced B (B3), and C tumors. Size of 8 cm or larger is an independent risk factor, even when patients with Masaoka stage III tumors are considered alone, and might identify candidates for preoperative therapy.
本研究旨在确定胸腺肿瘤切除术后复发的预测因素。
对1972年至2003年期间在单一机构接受胸腺肿瘤切除术的179例患者进行回顾性研究。
90%(161/179)的患者手术切除完整。中位随访115个月后,复发率为11%(20/179),肿瘤相关死亡率为7.8%(14/179),总死亡率为36.3%(65/179)。肿瘤复发与晚期别和组织学相关(P <.0001)。Masaoka I期(0)和II期(1.7%[1/59])之间的复发差异不显著。复发率与世界卫生组织肿瘤类型相关:A和AB型,0%;B1和B2型,8%(4/51);B3型,27%(14/51);C型,50%(2/4;P <.0001)。将肿瘤大小分为五分位数显示,8 cm处复发率升高(<8 cm,1.8%[2/113];≥8 cm,28%[18/64];P <.003)。多变量Cox模型显示,Masaoka分期(比值比,5.70;P <.001)、世界卫生组织组织学类型(比值比,5.77;P =.003)和大小(比值比,1.16;P =.001)是复发的独立预测因素。
通过合并I期和II期,Masaoka分期系统可简化为3个侵袭程度。世界卫生组织组织学类型在临床应用中可简化为A(A、AB)、早期B(B1、B2)、晚期B(B3)和C型肿瘤。8 cm或更大的肿瘤大小是一个独立的危险因素,即使仅考虑Masaoka III期肿瘤患者,它也可能识别出术前治疗的候选者。